{"disease":{"id":"human","name":"human"},"drugs":{"marketed":[{"drug_id":"bictegravir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Biktarvy","generic_name":"BICTEGRAVIR","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":70,"revenue":"13400","mechanism":"Biktarvy works by binding to the integrase enzyme, preventing the HIV virus from integrating its genetic material into the host cell's DNA."},{"drug_id":"dolutegravir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tivicay","generic_name":"DOLUTEGRAVIR","company_name":"GSK","drug_phase":"marketed","molecular_target":"Transmembrane protein 97","drug_class":"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":72,"revenue":"5200","mechanism":"Tivicay blocks the integrase enzyme, preventing HIV from integrating its genetic material into the host cell's DNA."},{"drug_id":"ibrance","indication_name":"Human epidermal growth factor 2 negative carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ibrance","generic_name":"Palbociclib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":88,"revenue":"4500","mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"palbociclib-in-combination-with-ai","indication_name":"Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women with estrogen receptor-positive (ER+), HER2-negative breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib in combination with AI","generic_name":"palbociclib-in-combination-with-ai","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CDK4/6","drug_class":"CDK inhibitor","quality_score":50,"revenue":"4122","mechanism":""},{"drug_id":"palbociclib-in-combination-with-ai","indication_name":"Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib in combination with AI","generic_name":"palbociclib-in-combination-with-ai","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CDK4/6","drug_class":"CDK inhibitor","quality_score":50,"revenue":"4122","mechanism":""},{"drug_id":"abemaciclib","indication_name":"Human epidermal growth factor 2 negative carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verzenio","generic_name":"abemaciclib","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/CDK6)","drug_class":"Kinase inhibitor","quality_score":78,"revenue":"3700","mechanism":"Abemaciclib inhibits CDK4 and CDK6, blocking Rb phosphorylation and G1/S cell cycle progression."},{"drug_id":"trastuzumab-deruxtecan","indication_name":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enhertu","generic_name":"trastuzumab-deruxtecan","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":63,"revenue":"2900","mechanism":"Enhertu works by binding to the HER2 protein and releasing a cytotoxic payload to kill cancer cells."},{"drug_id":"trastuzumab","indication_name":"Human epidermal growth factor 2 positive gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Herceptin","generic_name":"trastuzumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"HER2 receptor, subdomain IV","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"2900","mechanism":"HER2-targeted antibody-drug conjugate delivering microtubule inhibitor DM1 to HER2-overexpressing cells."},{"drug_id":"tenofovir-alafenamide","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vemlidy","generic_name":"TENOFOVIR ALAFENAMIDE","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":59,"revenue":"2800","mechanism":"Vemlidy works by inhibiting the HIV reverse transcriptase enzyme, preventing viral replication."},{"drug_id":"olaparib","indication_name":"Human epidermal growth factor 2 negative carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lynparza","generic_name":"olaparib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 2","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor [EPC]","quality_score":73,"revenue":"2600","mechanism":"Lynparza blocks the repair of DNA damage in cancer cells by inhibiting the enzyme PARP."},{"drug_id":"emtricitabine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emtriva","generic_name":"EMTRICITABINE","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":69,"revenue":"2400","mechanism":"Emtriva works by blocking the reverse transcriptase enzyme, which is necessary for HIV to replicate."},{"drug_id":"cabotegravir","indication_name":"Human immunodeficiency virus I infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vocabria","generic_name":"CABOTEGRAVIR","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor","quality_score":60,"revenue":"2100","mechanism":"Vocabria works by blocking the integrase enzyme, which is necessary for the virus to replicate."},{"drug_id":"tukysa","indication_name":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tukysa","generic_name":"tukysa","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ERBB2/ERBB3","drug_class":"Kinase Inhibitor [EPC]","quality_score":65,"revenue":"463","mechanism":"Tukysa blocks the activity of ERBB2 and ERBB3 proteins, which are involved in cancer cell growth and spread."},{"drug_id":"tucatinib","indication_name":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tukysa","generic_name":"tucatinib","company_name":"Seagen","drug_phase":"marketed","molecular_target":"ERBB2/ERBB3","drug_class":"Kinase Inhibitor [EPC]","quality_score":59,"revenue":"463","mechanism":"Tukysa works by blocking the ERBB2/ERBB3 receptors, which are involved in the growth and spread of cancer cells."},{"drug_id":"zolbetuximab","indication_name":"locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyloy","generic_name":"ZOLBETUXIMAB","company_name":"Astellas","drug_phase":"marketed","molecular_target":"","drug_class":"Claudin 18.2-directed Cytolytic Antibody [EPC]","quality_score":55,"revenue":"100","mechanism":"Vyloy works by binding to Claudin 18.2 on cancer cells, triggering their destruction."},{"drug_id":"zolbetuximab","indication_name":"locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyloy","generic_name":"ZOLBETUXIMAB","company_name":"Astellas","drug_phase":"marketed","molecular_target":"","drug_class":"Claudin 18.2-directed Cytolytic Antibody [EPC]","quality_score":55,"revenue":"100","mechanism":"Vyloy works by binding to Claudin 18.2 on cancer cells, triggering their destruction."},{"drug_id":"etravirine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intelence","generic_name":"ETRAVIRINE","company_name":"Janssen R And D","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 2","drug_class":"Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":"Intelence works by blocking the reverse transcriptase enzyme, which is essential for the replication of the HIV virus."},{"drug_id":"elvitegravir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitekta","generic_name":"ELVITEGRAVIR","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":"Vitekta blocks the integrase enzyme, preventing HIV from replicating."},{"drug_id":"margetuximab","indication_name":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Margenza","generic_name":"MARGETUXIMAB","company_name":"Macrogenics Inc","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":55,"revenue":null,"mechanism":"Margenza works by blocking the HER2/neu receptor, which is overexpressed in certain breast cancer cells, to prevent them from growing and multiplying."},{"drug_id":"raltegravir-use-ral-as-a-simplification-strategy","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Raltegravir (Use RAL as a simplification strategy)","company_name":"Hospital Carlos III, Madrid","drug_phase":"marketed","molecular_target":"C-C chemokine receptor type 1, Gag-Pol polyprotein, Integrase","drug_class":"Integrase inhibitors","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"famciclovir","indication_name":"Recurrent Mucocutaneous Herpes Simplex in Human Immunodeficiency Virus Infected Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Famvir","generic_name":"FAMCICLOVIR","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]","quality_score":59,"revenue":null,"mechanism":"Famvir works by inhibiting the replication of herpes simplex virus DNA through its action as a nucleoside analog DNA polymerase inhibitor."},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"vaccine-administration","indication_name":"Human Papillomavirus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vaccine Support Cp","generic_name":"Vaccine administration","company_name":"Women and Infants Hospital of Rhode Island","drug_phase":"marketed","molecular_target":"unknown","drug_class":"vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"zidovudine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retrovir","generic_name":"ZIDOVUDINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Thymidine kinase, cytosolic","drug_class":"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Retrovir works by mimicking the natural building blocks of DNA to prevent HIV from replicating."},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Human papillomavirus (HPV)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Human papillomavirus (HPV) booster","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Human papillomavirus (HPV) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Human papillomavirus (HPV) booster (pregnancy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Human papillomavirus (HPV) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Human papillomavirus (HPV) booster (adult)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Human papillomavirus (HPV) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Human papillomavirus (HPV) booster (pregnancy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Human papillomavirus (HPV) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"fuzeon","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fuzeon","company_name":"Trimeris","drug_phase":"phase_1","molecular_target":"Envelope glycoprotein, GP41, Transmembrane glycoprotein gp41","drug_class":"","quality_score":12,"revenue":null,"mechanism":""},{"drug_id":"pd-0332991","indication_name":"Human epidermal growth factor 2 negative carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PD-0332991","generic_name":"pd-0332991","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase TAO2","drug_class":"PD-0332991, 125mg, 3 cycles","quality_score":null,"revenue":null,"mechanism":"PD-0332991, 125mg, 3 cycles"},{"drug_id":"fosamprenavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lexiva","generic_name":"FOSAMPRENAVIR","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Protease Inhibitor","quality_score":56,"revenue":null,"mechanism":"Lexiva works by blocking the protease enzyme, which is necessary for HIV to replicate."},{"drug_id":"trastuzumab-dkst","indication_name":"Human epidermal growth factor 2 positive gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OGIVRI","generic_name":"TRASTUZUMAB-DKST","company_name":"MYLAN GMBH","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"margetuximab-cmkb","indication_name":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MARGENZA","generic_name":"MARGETUXIMAB-CMKB","company_name":"MACROGENICS INC","drug_phase":"marketed","molecular_target":"Low affinity immunoglobulin gamma Fc region receptor III-A, Receptor tyrosine-protein kinase erbB-2","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"viread","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Viread","company_name":"Replicor Inc.","drug_phase":"marketed","molecular_target":"Gag-Pol polyprotein, Reverse transcriptase/RNaseH","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"tesamorelin-acetate","indication_name":"Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Egrifta","generic_name":"TESAMORELIN ACETATE","company_name":"Theratechnologies","drug_phase":"marketed","molecular_target":"Growth hormone-releasing hormone receptor","drug_class":"Growth Hormone Releasing Factor Analog","quality_score":10,"revenue":null,"mechanism":"Egrifta works by mimicking the action of growth hormone-releasing hormone to stimulate the release of growth hormone."},{"drug_id":"lynparza","indication_name":"Human epidermal growth factor 2 negative carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lynparza","company_name":"University of Texas Southwestern Medical Center","drug_phase":"marketed","molecular_target":"Mono [ADP-ribose] polymerase PARP16, Tankyrase-1, Tankyrase-2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"amprenavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Agenerase","generic_name":"AMPRENAVIR","company_name":"GSK","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Protease Inhibitor","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ritonavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norvir","generic_name":"ritonavir","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C9","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Norvir works by blocking the cytochrome P450 3A enzyme, which helps increase the levels of other medications in the body."},{"drug_id":"didanosine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Videx","generic_name":"DIDANOSINE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"nelfinavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Viracept","generic_name":"NELFINAVIR","company_name":"Agouron Pharms","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Protease Inhibitor","quality_score":65,"revenue":null,"mechanism":"Viracept works by blocking the protease enzyme, which is essential for the replication of HIV."},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"atazanavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Reyataz","generic_name":"ATAZANAVIR","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"UDP-glucuronosyltransferase 1-1","drug_class":"Protease Inhibitor","quality_score":75,"revenue":null,"mechanism":"Reyataz works by blocking the protease enzyme, which is essential for the replication of HIV."},{"drug_id":"trazimera","indication_name":"Human epidermal growth factor 2 positive gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Herceptin","generic_name":"Trastuzumab-Qyyp","company_name":"Roche","drug_phase":"marketed","molecular_target":"HER2 (c-erbB2) proto-oncogene transmembrane receptor protein","drug_class":"HER2/neu receptor antagonist monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Trastuzumab inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity."},{"drug_id":"lopinavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kaletra","generic_name":"LOPINAVIR","company_name":"Abbvie Deutschland Gmbh Co. Kg","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":"Kaletra blocks the protease enzyme, preventing the HIV virus from replicating."},{"drug_id":"nevirapine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Viramune","generic_name":"NEVIRAPINE","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Viramune works by binding to the reverse transcriptase enzyme, preventing HIV from replicating."},{"drug_id":"foscarnet","indication_name":"Encephalitis caused by human herpesvirus 6 infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foscavir","generic_name":"FOSCARNET","company_name":"Clinigen Hlthcare","drug_phase":"marketed","molecular_target":"","drug_class":"Pyrophosphate Analog DNA Polymerase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Foscarnet works by directly inhibiting viral DNA polymerase, preventing the replication of viral DNA."},{"drug_id":"enfuvirtide","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fuzeon","generic_name":"ENFUVIRTIDE","company_name":"Roche","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus 1 Fusion Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl4650215","indication_name":"endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"INAVOLISIB","company_name":"Genentech Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":"Itovebi works by blocking a specific enzyme called PIK3CA, which is involved in the growth and spread of cancer cells."},{"drug_id":"doravirine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pifeltro","generic_name":"DORAVIRINE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Pifeltro works by blocking the reverse transcriptase enzyme, which is essential for the replication of the HIV virus."},{"drug_id":"herceptin","indication_name":"Human epidermal growth factor 2 positive gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Herceptin","company_name":"National Cancer Institute (NCI)","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"norvir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Norvir","company_name":"Saint Michael's Medical Center","drug_phase":"marketed","molecular_target":"UDP-glucuronosyltransferase 1-1, Cytochrome P450 2C9, Multidrug and toxin extrusion protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rescriptor","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rescriptor","company_name":"Pfizer","drug_phase":"phase_2","molecular_target":"Malate dehydrogenase cytoplasmic , ATP-binding cassette sub-family G member 2, Histamine H4 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"trastuzumab-herceptin","indication_name":"Human epidermal growth factor 2 positive gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trastuzumab (Herceptin)","generic_name":"trastuzumab-herceptin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"sustiva","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sustiva","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cholesterol 24-hydroxylase, ATP-binding cassette sub-family G member 2, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tivicay","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tivicay","company_name":"St Stephens Aids Trust","drug_phase":"marketed","molecular_target":"Transmembrane protein 97, Integrase, Integrase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fexinidazole","indication_name":"Human African Trypanosomiasis (HAT)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fexinidazole","generic_name":"FEXINIDAZOLE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":49,"revenue":null,"mechanism":"Fexinidazole works by releasing free radicals that damage the DNA of Trypanosoma brucei gambiense, ultimately killing the parasite."},{"drug_id":"viramune","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Viramune","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Gag-Pol polyprotein, Pol polyprotein, Reverse transcriptase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tecovirimat-monohydrate","indication_name":"Treatment of Human Smallpox Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TECOVIRIMAT MONOHYDRATE","company_name":"","drug_phase":"marketed","molecular_target":"variola (smallpox) virus","drug_class":"Orthopoxvirus VP37 Envelope Wrapping Protein Inhibitor [EPC]","quality_score":49,"revenue":null,"mechanism":"Tecovirimat is an antiviral drug that targets the variola (smallpox) virus."},{"drug_id":"ibalizumab","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trogarzo","generic_name":"IBALIZUMAB","company_name":"Taimed Biologics Usa","drug_phase":"marketed","molecular_target":"T-cell surface glycoprotein CD4","drug_class":"CD4-directed Blocking Antibody [EPC]","quality_score":48,"revenue":null,"mechanism":"Trogarzo works by binding to the CD4 receptor on T-cells, preventing HIV from entering and infecting these cells."},{"drug_id":"fostemsavir","indication_name":"Human immunodeficiency virus I infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rukobia","generic_name":"FOSTEMSAVIR","company_name":"GSK","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Rukobia works by blocking the potassium voltage-gated channel subfamily H member 2, which is involved in the replication of the human immunodeficiency virus 1."},{"drug_id":"darunavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prezista","generic_name":"DARUNAVIR","company_name":"Janssen Prods","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1","drug_class":"Protease Inhibitor [EPC]","quality_score":62,"revenue":null,"mechanism":"Darunavir works by blocking the protease enzyme, which is essential for the replication of the HIV virus."},{"drug_id":"invirase","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Invirase","company_name":"Saint Michael's Medical Center","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, Multidrug resistance protein 1","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"brincidofovir","indication_name":"human smallpox disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tembexa","generic_name":"BRINCIDOFOVIR","company_name":"Emergent Biodefense","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":57,"revenue":null,"mechanism":"Tembexa works by inhibiting the replication of viruses."},{"drug_id":"brincidofovir","indication_name":"diseases other than human smallpox disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tembexa","generic_name":"BRINCIDOFOVIR","company_name":"Emergent Biodefense","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":57,"revenue":null,"mechanism":"Tembexa works by inhibiting the replication of viruses."},{"drug_id":"enhertu","indication_name":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Enhertu","company_name":"Washington D.C. Veterans Affairs Medical Center","drug_phase":"marketed","molecular_target":"DNA topoisomerase 1, Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"delavirdine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rescriptor","generic_name":"DELAVIRDINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Histamine H4 receptor","drug_class":"Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"abacavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ziagen","generic_name":"ABACAVIR","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor","quality_score":60,"revenue":null,"mechanism":"Abacavir works by mimicking a building block of DNA, tricking the virus into incorporating it into its genetic material and preventing replication."},{"drug_id":"efavirenz","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sustiva","generic_name":"EFAVIRENZ","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cholesterol 24-hydroxylase","drug_class":"Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Sustiva works by binding to the reverse transcriptase enzyme, preventing the replication of viral RNA."},{"drug_id":"lamivudine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epivir","generic_name":"LAMIVUDINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Deoxycytidine kinase","drug_class":"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":66,"revenue":null,"mechanism":"Epivir works by mimicking the building blocks of DNA to prevent the replication of viral genetic material."},{"drug_id":"indinavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crixivan","generic_name":"INDINAVIR","company_name":"Merck & Co.","drug_phase":"discontinued","molecular_target":"Cytochrome P450 3A4","drug_class":"indinavir","quality_score":0,"revenue":null,"mechanism":"Crixivan blocks the replication of HIV by inhibiting the protease enzyme, which is essential for the virus to produce new particles."},{"drug_id":"fexinidazole","indication_name":"Human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fexinidazole","generic_name":"FEXINIDAZOLE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":49,"revenue":null,"mechanism":"Fexinidazole works by releasing free radicals that damage the DNA of Trypanosoma brucei gambiense, ultimately killing the parasite."},{"drug_id":"cobicistat","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tybost","generic_name":"COBICISTAT","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":"Tybost works by blocking the enzyme Cytochrome P450 3A, which is responsible for breaking down many other medications."}],"pipeline":[],"offLabel":[],"totalMarketed":78,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05858450","title":"This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.","phase":"","overall_status":"COMPLETED","enrollment_count":3442996,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04590066","title":"Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy","phase":"NA","overall_status":"COMPLETED","enrollment_count":734383,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT05365048","title":"Provider Recommendation and HPV Vaccination","phase":"NA","overall_status":"RECRUITING","enrollment_count":301201,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT01078220","title":"Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)","phase":"","overall_status":"COMPLETED","enrollment_count":189629,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05229679","title":"HPV-based Screening Among Women 23-29 Years of Age","phase":"NA","overall_status":"RECRUITING","enrollment_count":180000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT03335644","title":"The NutriNet-Santé Study","phase":"","overall_status":"RECRUITING","enrollment_count":170000,"lead_sponsor_name":"University of Paris 13","has_results":false},{"nct_id":"NCT04576962","title":"County Level Correlates of HPV Vaccine Series Completion Among Children Ages 11-14 Years in Indiana","phase":"","overall_status":"COMPLETED","enrollment_count":122152,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT01567813","title":"Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)","phase":"","overall_status":"COMPLETED","enrollment_count":114035,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06831383","title":"The STOP-HPV Scale Up Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT06604663","title":"Data Science and Qualitative Research for Decision Support in the HIV Care Cascade","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":80000,"lead_sponsor_name":"Brown University","has_results":false},{"nct_id":"NCT02993965","title":"State Immunization Information Systems to Improve HPV Vaccination Rates","phase":"NA","overall_status":"COMPLETED","enrollment_count":77716,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT06566534","title":"Personalized Nudging to Increase Influenza Vaccinations","phase":"NA","overall_status":"COMPLETED","enrollment_count":77482,"lead_sponsor_name":"Geisinger Clinic","has_results":false},{"nct_id":"NCT04565353","title":"Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates","phase":"NA","overall_status":"COMPLETED","enrollment_count":74811,"lead_sponsor_name":"University of Pennsylvania","has_results":true},{"nct_id":"NCT03294473","title":"Centralized Reminder Recall - Flu RCT2","phase":"NA","overall_status":"COMPLETED","enrollment_count":70190,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT05536674","title":"SMS Reminders to Strengthen Demand for HPV Vaccination in Georgia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":55176,"lead_sponsor_name":"The Behavioural Insights Team","has_results":false},{"nct_id":"NCT01077856","title":"GARDASIL™ Vaccine Impact in Population Study (V501-033)","phase":"","overall_status":"COMPLETED","enrollment_count":54516,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03748160","title":"Herd Immunity and Influenza Vaccine Uptake","phase":"NA","overall_status":"COMPLETED","enrollment_count":48125,"lead_sponsor_name":"Finnish Institute for Health and Welfare","has_results":false},{"nct_id":"NCT05996783","title":"Cervical Cancer Screening Based on First-void Urine Self-sampling to Reach un(Der)-Screened Women: ScreenUrSelf Trial","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48000,"lead_sponsor_name":"Universiteit Antwerpen","has_results":false},{"nct_id":"NCT07259616","title":"Incidence of Cervical Cancer in HPV-positive Women With Low-grade Cytological Abnormalities","phase":"","overall_status":"COMPLETED","enrollment_count":46079,"lead_sponsor_name":"Gynaecologisch Oncologisch Centrum Zuid","has_results":false},{"nct_id":"NCT05540522","title":"A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":45789,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04371887","title":"Comparing Strategies for Implementing Primary HPV Screening","phase":"NA","overall_status":"UNKNOWN","enrollment_count":45000,"lead_sponsor_name":"Chun Chao","has_results":false},{"nct_id":"NCT05394961","title":"Factors Associated With Decisions to Withhold or Withdraw Intensive Care","phase":"","overall_status":"COMPLETED","enrollment_count":33256,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT04679675","title":"Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":32771,"lead_sponsor_name":"Kaiser Permanente","has_results":true},{"nct_id":"NCT07089966","title":"HIV Testing Counselor-led Care to Catalyze Integration of PrEP Delivery in Family Planning Clinics","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":30000,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT06557954","title":"Cervical Cytology DNA Methylation for Cervical Cancer Screening","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT03180034","title":"Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":27945,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03278067","title":"Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines: Pilot Study in England","phase":"","overall_status":"COMPLETED","enrollment_count":23939,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03180060","title":"Meta-Analysis of Stress Myocardial Perfusion Imaging","phase":"","overall_status":"COMPLETED","enrollment_count":23051,"lead_sponsor_name":"American British Cowdray Medical Center","has_results":false},{"nct_id":"NCT07161739","title":"Vaccination Nudges From Pharmacists","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT02893878","title":"Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines","phase":"","overall_status":"COMPLETED","enrollment_count":19334,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02538952","title":"Evaluating Accuracy, Impact, and Operational Challenges of GeneXpert Use for TB Case Finding Among HIV-infected Persons","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":18696,"lead_sponsor_name":"Centers for Disease Control and Prevention","has_results":false},{"nct_id":"NCT06207929","title":"Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections","phase":"","overall_status":"COMPLETED","enrollment_count":18157,"lead_sponsor_name":"Evidation Health","has_results":false},{"nct_id":"NCT03726151","title":"Comparative Effectiveness of System Interventions to Increase HPV Vaccine Receipt in FQHCs","phase":"NA","overall_status":"UNKNOWN","enrollment_count":17000,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT04525833","title":"Liver Disease and Other Systemic Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","has_results":false},{"nct_id":"NCT04226313","title":"Self-sampling for Non-attenders to Cervical Cancer Screening","phase":"NA","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"The Institute of Molecular and Translational Medicine, Czech Republic","has_results":false},{"nct_id":"NCT04746872","title":"Alinity m HR HPV Specimen Collection Study From Women Undergoing Routine Cervical Cancer Screening","phase":"","overall_status":"COMPLETED","enrollment_count":14935,"lead_sponsor_name":"Abbott Molecular","has_results":false},{"nct_id":"NCT00543543","title":"Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":14840,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04099628","title":"Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring","phase":"NA","overall_status":"COMPLETED","enrollment_count":13747,"lead_sponsor_name":"Institut de Recherche pour le Developpement","has_results":false},{"nct_id":"NCT04038333","title":"Financing Strategies of Influenza Vaccination in China","phase":"","overall_status":"COMPLETED","enrollment_count":13542,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT04561050","title":"Prediction of Massive Transfusion in Trauma Patients","phase":"","overall_status":"COMPLETED","enrollment_count":13222,"lead_sponsor_name":"Centre Hospitalier Universitaire Vaudois","has_results":false},{"nct_id":"NCT07200414","title":"Strengthening HPV Vaccination and Adolescent Health Research Program in Nigeria (SHARP)","phase":"NA","overall_status":"COMPLETED","enrollment_count":12654,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT05932576","title":"A Multicenter Cohort Study Assessing the Efficacy and Adverse Effects of HPV Vaccination in Chinese Women","phase":"","overall_status":"UNKNOWN","enrollment_count":12000,"lead_sponsor_name":"Fujian Maternity and Child Health Hospital","has_results":false},{"nct_id":"NCT04646954","title":"DNA Methylation Testing for the Screening of Uterine Cervical Lesion","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":12000,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT05668572","title":"A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":12000,"lead_sponsor_name":"Beijing Health Guard Biotechnology, Inc","has_results":false},{"nct_id":"NCT02733068","title":"A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":12000,"lead_sponsor_name":"Shanghai Zerun Biotechnology Co.,Ltd","has_results":false},{"nct_id":"NCT03239795","title":"Promoting Influenza Vaccination In General Practice Waiting Rooms","phase":"NA","overall_status":"COMPLETED","enrollment_count":10597,"lead_sponsor_name":"Christophe Berkhout","has_results":false},{"nct_id":"NCT06815939","title":"Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"DL Analytics","has_results":false},{"nct_id":"NCT03961178","title":"A Cohort Study for the Following up of Conization","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT05309122","title":"Cervical Cancer Screening Strategies","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Lei Li","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}